위식도역류질환 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약제 유형별, 지역별, 부문별 예측(2025-2030년)

Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

위식도역류질환 치료제 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 위식도역류질환 치료제 시장 규모는 2030년까지 57억 7,000만 달러에 달할 것으로 예측됩니다.

이 시장은 2025-2030년에 걸쳐 CAGR 2.0%를 나타낼 것으로 예측됩니다. 이 성장은 위식도 역류증 및 기타 위장 질환의 유병률 증가로 인한 것입니다. 또한 라이프 스타일과 식습관 변화, GERD 관리 장비와 관련된 성공률이 낮고, 셀프 메디케이션 수요 증가가 산업 성장을 더욱 촉진하고 있습니다.

위식도 역류 및 기타 위 질환의 유병률 증가는 시장 성장을 가속하고 있습니다. 예를 들어, 전체 인구의 약 13.98%가 GERD를 앓고 있는 것으로 추정되며, 이는 전 세계적으로 약 10억 3,000만 명이 GERD로 고통받고 있는 것에 해당합니다. 이환율 증가는 적절한 치료의 필요성을 뒷받침합니다. 미확인 문제를 치료하기 위해 상용 약물을 사용하는 사람은 위험이 높을 수 있습니다. 치료되지 않은 GERD는 불편함을 증가시킬 뿐만 아니라 추가적인 의료 문제를 일으킬 수 있습니다.

GERD의 치료는 일반적으로 생활 습관의 개선, 외과적 치료, 내과적 치료를 포함합니다. 생활습관의 개선에 반응하지 않는 환자에게는 치료적 개입이 이루어집니다. 제산제, PPI 및 히스타민(H2) 수용체 길항제(H2RA)와 같은 분비 억제제, 운동 촉진제 등이 치료로 사용됩니다. 파모티딘과 시메티딘은 미국 식품의약국(FDA)의 인가를 받은 2개의 H2RA로 현재 미국에서 시판되고 있습니다. 다른 H2RA에서 사용되는 빈도가 높은 라니티딘은 활성 성분에 예기치 않은 불순물이 포함되어 있어 잠재적인 건강 위험과 안전 문제로 회수되었습니다.

또한, 주요 업체들은 위식도 역류 질환 치료제를 통합하는 데 주력하고 있습니다. 예를 들어, 2022년 5월, Phatom Pharmaceuticals는 Vonoprazan의 FDA 승인을 발표했습니다. Vonoprazan은 모든 등급의 미란 식도염을 가진 성인의 치료이며 가슴 앓이의 치유와 완화를 목표로합니다. 게다가 JB 파마는 2022년 11월 산 역류와 가슴앓이를 빠르게 완화하는 신규 제제 '런래프트'를 발매했습니다.

위식도역류질환 치료제 시장 보고서 하이라이트

• 제산제 부문은 2024년 위식도역류질환 치료제 시장을 독점했으며, 제산제는 위내 산에 대항하는 경향이 있으므로 신속하고 단시간에 증상을 완화할 수 있습니다.
• 추가 의료 문제로 이어지는 불필요한 상태로 인한 치료되지 않은 상태는 적절한 치료에 대한 수요를 추진하고 있습니다.
• 신흥국 시장에서 활동하는 주요 진출기업은 GERD를 통해 발생하는 불편한 상태를 억제하는 데 도움이 되는 약물 개발에 주력하고 있습니다.
• 북미가 가장 큰 시장 점유율을 차지하고 있지만, 이는 장애를 가진 환자의 재활을 촉진하는 진단 기술의 기술적 진보가 증가하고 있기 때문입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 위식도역류질환 치료제 시장의 변수, 동향, 범위

• 시장 계통의 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 위식도역류질환 치료제 시장 : 약제 유형별 비즈니스 분석

• 약제 유형별 시장 점유율(2024년·2030년)
• 약제 유형 부문 대시보드
• 시장 규모와 예측과 동향 분석, 약제 유형별(2018-2030년)
• 제산제
• H2 수용체 차단제
• 양성자 펌프 억제제(PPI)
• 프로-키네틱 에이전트

제5장 위식도역류질환 치료제 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석(2024년·2030년)
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석(2018-2030년)
• 북미
  • 국가별(2018-2030년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별(2018-2030년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 국가별(2018-2030년)
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별(2018-2030년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별(2018-2030년)
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제6장 경쟁 구도

• 참가자 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일/상장 기업
  • AstraZeneca
  • Eisai Co., Ltd.
  • GSK plc.
  • Takeda Pharmaceutical Company Limited
  • Ironwood
  • Johnson & Johnson Services, Inc.
  • SFJ Pharmaceuticals
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc.
  • Camber Pharmaceuticals, Inc.

KTH

영문 목차

영문목차

Gastroesophageal Reflux Disease Therapeutics Market Growth & Trends:

The global gastroesophageal reflux disease therapeutics market size is anticipated to reach USD 5.77 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 2.0% from 2025 to 2030. The growth is attributed to increasing prevalence of gastroesophageal reflux disease and other gastrointestinal diseases. Moreover, change in lifestyle and food habits, low success rates associated with GERD management devices and increasing demand for self-medication is further propelling the industry growth.

Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.

Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.

Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.

Gastroesophageal Reflux Disease Therapeutics Market Report Highlights:

• Antacids segment dominated the gastroesophageal reflux disease treatment market in 2024 and is attributable to the rapid and quick relief offered by antacids, as they tend to counteract the acidity inside the stomach.
• Untreated condition owing to unnecessary condition that leads to additional medical issues is propelling the demand for proper therapeutics.
• Key players operating in the market are focusing on developing medications that helps in curbing the uncomfortable condition occurring through GERD.
• North America held the largest market share which can be attributed to the increasing technological advancements in diagnostics technologies that facilitate rehabilitation of disabled patients.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Gastroesophageal Reflux Disease Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Business Analysis

• 4.1. Drug Type Market Share, 2024 & 2030
• 4.2. Drug Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 4.4. Antacids
  • 4.4.1. Antacids Market, 2018 - 2030 (USD Million)
• 4.5. H2 Receptor Blockers
  • 4.5.1. H2 Receptor Blockers Market, 2018 - 2030 (USD Million)
• 4.6. Proton Pump Inhibitors (PPIs)
  • 4.6.1. Proton Pump Inhibitors (PPIs) Market, 2018 - 2030 (USD Million)
• 4.7. Pro-kinetic Agents
  • 4.7.1. Pro-kinetic Agents Market, 2018 - 2030 (USD Million)

Chapter 5. Gastroesophageal Reflux Disease Therapeutics Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2024 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.4. North America
  • 5.4.1. North America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Regulatory Framework
    • 5.4.2.3. Competitive Insights
    • 5.4.2.4. U.S. Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Regulatory Framework
    • 5.4.3.3. Competitive Insights
    • 5.4.3.4. Canada Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Regulatory Framework
    • 5.4.4.3. Competitive Insights
    • 5.4.4.4. Mexico Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Regulatory Framework
    • 5.5.2.3. Competitive Insights
    • 5.5.2.4. UK Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Regulatory Framework
    • 5.5.3.3. Competitive Insights
    • 5.5.3.4. Germany Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Regulatory Framework
    • 5.5.4.3. Competitive Insights
    • 5.5.4.4. France Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Regulatory Framework
    • 5.5.5.3. Competitive Insights
    • 5.5.5.4. Italy Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Regulatory Framework
    • 5.5.6.3. Competitive Insights
    • 5.5.6.4. Spain Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Norway
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Regulatory Framework
    • 5.5.7.3. Competitive Insights
    • 5.5.7.4. Norway Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Denmark
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Regulatory Framework
    • 5.5.8.3. Competitive Insights
    • 5.5.8.4. Denmark Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Sweden
    • 5.5.9.1. Key Country Dynamics
    • 5.5.9.2. Regulatory Framework
    • 5.5.9.3. Competitive Insights
    • 5.5.9.4. Sweden Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Regulatory Framework
    • 5.6.2.3. Competitive Insights
    • 5.6.2.4. Japan Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Regulatory Framework
    • 5.6.3.3. Competitive Insights
    • 5.6.3.4. China Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Regulatory Framework
    • 5.6.4.3. Competitive Insights
    • 5.6.4.4. India Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. South Korea
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Regulatory Framework
    • 5.6.5.3. Competitive Insights
    • 5.6.5.4. South Korea Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. Australia
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Regulatory Framework
    • 5.6.6.3. Competitive Insights
    • 5.6.6.4. Australia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Regulatory Framework
    • 5.6.7.3. Competitive Insights
    • 5.6.7.4. Thailand Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Regulatory Framework
    • 5.7.2.3. Competitive Insights
    • 5.7.2.4. Brazil Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Regulatory Framework
    • 5.7.3.3. Competitive Insights
    • 5.7.3.4. Argentina Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. MEA Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Regulatory Framework
    • 5.8.2.3. Competitive Insights
    • 5.8.2.4. South Africa Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Regulatory Framework
    • 5.8.3.3. Competitive Insights
    • 5.8.3.4. Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Regulatory Framework
    • 5.8.4.3. Competitive Insights
    • 5.8.4.4. UAE Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key Country Dynamics
    • 5.8.5.2. Regulatory Framework
    • 5.8.5.3. Competitive Insights
    • 5.8.5.4. Kuwait Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. AstraZeneca
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Eisai Co., Ltd.
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. GSK plc.
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Takeda Pharmaceutical Company Limited
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. Ironwood
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. Johnson & Johnson Services, Inc.
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. SFJ Pharmaceuticals
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. Sebela Pharmaceuticals
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Phathom Pharmaceuticals, Inc.
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Product Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. Camber Pharmaceuticals, Inc.
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Product Benchmarking
    • 6.5.10.4. Strategic Initiatives

관련자료